Search
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Alefacept
go.drugbank.com/drugs/DB00092ApprovedWithdrawnProduced by CHO cells, mW is 91.4 kD. … Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of
Gimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalBy mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary … It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408].
Anidulafungin
go.drugbank.com/drugs/DB00362ApprovedAnidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. … There is preliminary evidence that it has a similar safety profile to caspofungin.
Paraldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.
Zapomeran
go.drugbank.com/drugs/DB21761ApprovedSelf-amplification allows for the use of lower doses while providing higher immunogenicity compared to a conventional mRNA COVID-19 vaccine. … [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.
Valganciclovir
go.drugbank.com/drugs/DB01610ApprovedInvestigationalAfter oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. … Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.
Ribociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalThese proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali. … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
Mixtures: Kisqali Femara Co-pack, Kisqali Femara Co-packMifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalIts inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.
Phenoxypropazine
go.drugbank.com/drugs/DB09251ApprovedWithdrawnIt was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome